The shares of Clovis Oncology, Inc. (NASDAQ:CLVS) has been pegged with a rating of Neutral by BofA/Merrill in its latest research note that was published on August 13th, 2019. BofA/Merrill wasn’t the only research firm that published a report of Clovis Oncology, Inc., with other equities research analysts also giving their opinion on the stock. Guggenheim advised investors in its research note published on August 2nd, 2019, to Neutral the CLVS stock. The stock had earned Sell rating from Goldman when it published its report on May 29th, 2019. The stock was given Buy rating by H.C. Wainwright in its report released on April 15th, 2019, the day when the price target on the stock was placed at $37. H.C. Wainwright was of a view that CLVS is Buy in its latest report on February 13th, 2019 while giving it a price target of $40. Leerink Partners thinks that CLVS is worth Outperform rating. This was contained in the firm’s report on December 4th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $22.55. The price of the stock the last time has raised by 9.42% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 22.41.
The shares of the company added by 0.35% during the trading session on Tuesday, reaching a low of $5.36 while ending the day at $5.69. During the trading session, a total of 6.42 million shares were traded which represents a -161.97% decline from the average session volume which is 2.45M shares. CLVS had ended its last session trading at 5.67. Clovis Oncology, Inc. currently has a market cap of $319.15M while its P/E earnings growth sits at 2.68, with a beta of 1.87. CLVS 52-week low price stands at $5.20 while its 52-week high price is $37.27.
The company in its last quarterly report recorded -$1.63 earnings per share which is above the -$1.74 predicted by most analysts. The Clovis Oncology, Inc. generated $33.12 million in revenue during the last quarter, which is slightly higher than the $32.24 million predicted by analysts. In the second quarter last year, the firm recorded -$1.88 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -15.34%. Clovis Oncology, Inc. has the potential to record -7.49 EPS for the current fiscal year, according to equities analysts.
Investment analysts at H.C. Wainwright published a research note on December 19th, 2016 where it informed investors and clients that Histogenics Corporation (NASDAQ:HSGX) is now rated as Buy. Their price target on the stock stands at $3.50. Guggenheim also rated HSGX as Downgrade on August 2nd, 2019, with its price target of $130 suggesting that HSGX could surge by 96.2% from its current share price. Even though the stock has been trading at $0.20/share, analysts expect it to surge higher by -2.92% to reach $5.00/share. It started the day trading at $0.195 and traded between $0.187 and $0.19 throughout the trading session.
A look at its technical shows that HSGX’s 50-day SMA is 0.20 while its 200-day SMA stands at 0.24. At the moment, only of Histogenics Corporation shares were sold short. The company’s average trading volume currently stands at 6.64M shares, which means that the short-interest ratio is just 0.67 days. Over the past seven days, the company moved, with its shift of 3.72%. Looking further, the stock has dropped -1.61% over the past 90 days while it gained 44.58% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more HSGX shares, increasing its portfolio by +85.65% during the last quarter. This move now sees The Vanguard Group Inc purchasing 1,580,148 shares in the last quarter, thus it now holds 3,424,966 shares of HSGX, with a total valuation of $616,494.
Similarly, Palo Alto Investors LP decreased its Histogenics Corporation shares by 0.00% during the recently filed quarter. After selling 0 shares in the last quarter, the firm now controls 302,922 shares of Histogenics Corporation which are valued at $54,526. In the same vein, Geode Capital Management LLC decreased its Histogenics Corporation shares by during the most recent reported quarter. The firm sold 0 shares during the quarter which decreased its stakes to 291,743 shares and is now valued at $52,514. Following these latest developments, around 6.44% of Histogenics Corporation stocks are owned by institutional investors and hedge funds.